| Citation: |
LI Zhijun, WU Song, LI Cheng, MA En. Clinical significance of serum microRNA-128-3p in patients with restenosis after interventional treatment of lower extremity arteriosclerosis[J]. Journal of Clinical Medicine in Practice, 2022, 26(10): 1-6. DOI: 10.7619/jcmp.20220021
|
To investigate the predictive value of serum microRNA-128-3p (miR-128-3p) for in-stent restenosis (ISR) after endovascular intervention in patients with lower extremity atherosclerotic occlusive disease (LEAOD).
A total of 406 LEAOD patients undergoing endovascular interventional therapy were recruited as study objects.At 6 months of follow-up, patients were divided into restenosis group (n=79) and the non-restenosis group (n=327).The levels of serum miR-128-3p were detected by real-time fluorescent quantitative polymerase chain reaction (qRT-PCR), and the levels of serum interleukin (IL)-6, IL-8 and metalloproteinase tissue inhibitor 1(TIMP-1) were detected by enzyme-linked immunosorbent assay.
The levels of serum miR-128-3p levels after surgery in both groups were lower than before surgery, and the serum miR-128-3p levels before and after surgery in the restenosis group were higher than those in the non-restenosis group, the differences were statistically significant (P < 0.05).Receiver operating characteristic curve analysis showed that area under curve of preoperative serum miR-128-3p level in predicting ISR was 0.712(95%CI, 0.644 to 0.781).The miR-128-3p levels were significantly higher in patients with diabetes, hypertension or age≥50 years in the restenosis group (P < 0.05).Age≥50 years, Fontaine stage of Ⅲ to Ⅳ, history of hypertension and diabetes mellitus, and elevated preoperative serum miR-128-3p expression were all independent risk factors for postoperative restenosis (P < 0.05).Pearson correlation analysis showed that preoperative serum miR-128-3p expression was significantly positively correlated with serum IL-6 or IL-8 levels (rs=0.646, 0.621, P < 0.001), negatively correlated with TIMP-1 levels (rs=-0.759, P < 0.001).
Serum miR-128-3p level may be a specific biomarker of ISR in patients with LEAOD after endovascular intervention.
| [1] |
宫明莲, 毛懿, 柳景华. 冠状动脉支架内慢性完全闭塞的介入治疗[J]. 中国循环杂志, 2021, 36(9): 911-915. doi: 10.3969/j.issn.1000-3614.2021.09.014
|
| [2] |
王聪霞, 贾珊. 冠状动脉支架内再狭窄发生机制的研究进展[J]. 西安交通大学学报: 医学版, 2018, 39(3): 303-309. https://www.cnki.com.cn/Article/CJFDTOTAL-XAYX201803001.htm
|
| [3] |
ZHANG J, GAO F D, NI T J, et al. Linc-POU3F3 is overexpressed in in-stent restenosis patients and induces VSMC phenotypic transformation via POU3F3/miR-449a/KLF4 signaling pathway[J]. Am J Transl Res, 2019, 11(7): 4481-4490.
|
| [4] |
FARINA F M, HALL I F, SERIO S, et al. miR-128-3p is a novel regulator of vascular smooth muscle cell phenotypic switch and vascular diseases[J]. Circ Res, 2020, 126(12): e120-e135.
|
| [5] |
DINESCH V, DINESCH M, BURUIAN M. Drug-eluting stent in-stent restenosis and re-restenosis: a hard time story[J]. J Saudi Heart Assoc, 2017, 29(2): 73-74. doi: 10.1016/j.jsha.2016.12.001
|
| [6] |
YU Y P, TAN L. The vulnerability of vessels involved in the role of embolism and hypoperfusion in the mechanisms of ischemic cerebrovascular diseases[J]. Biomed Res Int, 2016, 2016: 8531958.
|
| [7] |
曹位平, 王盛尧, 罗永全, 等. STEMI患者PCI治疗前外周血miR-1、miR-21表达水平与细胞因子、氧化应激及治疗后冠状动脉再狭窄的关系[J]. 岭南心血管病杂志, 2021, 27(2): 127-131. doi: 10.3969/j.issn.1007-9688.2021.02.02
|
| [8] |
尹培永, 崔小红, 熊婷, 等. 基于数据挖掘分析microRNAs在冠状动脉支架内再狭窄中的调控机制[J]. 生物技术通讯, 2019, 30(4): 496-501, 570. doi: 10.3969/j.issn.1009-0002.2019.04.007
|
| [9] |
梁慧敏, 李玉珠, 郑永丽, 等. miR-132在动脉粥样硬化中的表达及对缺氧诱导的血管内皮细胞增殖凋亡的影响[J]. 中国老年学杂志, 2019, 39(9): 2228-2231. doi: 10.3969/j.issn.1005-9202.2019.09.057
|
| [10] |
郑茜, 张勇, 杨东伟. miR-126通过MAPK信号通路抑制oxLDL处理的血管平滑肌细胞增殖和迁移[J]. 中国免疫学杂志, 2018, 34(2): 192-198. doi: 10.3969/j.issn.1000-484X.2018.02.007
|
| [11] |
杨吉鹏, 邱翔, 李琛, 等. miR-128-3p靶向抑制HOXA5调控多形性胶质母细胞瘤的增殖、侵袭与凋亡[J]. 肿瘤防治研究, 2021, 48(1): 12-18. doi: 10.3971/j.issn.1000-8578.2021.20.0595
|
| [12] |
LAN S S, ALBINSSON S. Regulation of IRS-1, insulin signaling and glucose uptake by miR-143/145 in vascular smooth muscle cells[J]. Biochem Biophys Res Commun, 2020, 529(1): 119-125. doi: 10.1016/j.bbrc.2020.05.148
|
| [13] |
祖雄林, 周旭, 陈金波, 等. 膀胱癌中miR-128与血管内皮生长因子C的靶向调控关系[J]. 中国现代医学杂志, 2015, 25(25): 38-44. doi: 10.3969/j.issn.1005-8982.2015.25.009
|
| [14] |
QU C, LIU X, GUO Y, et al. miR-128-3p inhibits vascular smooth muscle cell proliferation and migration by repressing FOXO4/MMP9 signaling pathway[J]. Mol Med, 2020, 26(1): 116. doi: 10.1186/s10020-020-00242-7
|
| [15] |
VISTBAKKA J, SUMELAHTI M L, LEHTIMÄKI T, et al. Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients[J]. Acta Neurol Scand, 2018, 138(2): 130-136. doi: 10.1111/ane.12921
|
| [16] |
ELNAGGAR M A, SEO S H, GOBAA S, et al. Nitric oxide releasing coronary stent: a new approach using layer-by-layer coating and liposomal encapsulation[J]. Small, 2016, 12(43): 6012-6023. doi: 10.1002/smll.201600337
|
| [17] |
JIANG F, ZHANG X, LU Y M, et al. Elevated level of miR-17 along with decreased levels of TIMP-1 and IL-6 in plasma associated with the risk of in-stent restenosis[J]. Biosci Trends, 2019, 13(5): 423-429. doi: 10.5582/bst.2019.01274
|
| [18] |
荣钰, 董莉. 血清MMP-9, TIMP-1及VEGF水平检测对冠状动脉支架内再狭窄诊断的研究进展[J]. 现代检验医学杂志, 2021, 36(1): 161-164. https://www.cnki.com.cn/Article/CJFDTOTAL-SXYN202101040.htm
|
| [19] |
郭玲, 何静, 崔莉, 等. 白细胞介素6对人脐静脉血管内皮细胞-间质细胞转化的作用[J]. 中华烧伤杂志, 2021, 37(5): 420-428.
|
| [20] |
丁静, 骆倩. 阿托伐他汀治疗急性脑梗死对患者血清hs-CRP、IL-6、IL-8及MMP-9水平的影响[J]. 河北医药, 2019, 41(1): 85-88. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYZ201901020.htm
|
| [21] |
赵莉莉, 宋衍秋, 张莹, 等. 人金属蛋白酶1组织抑制剂基因表达对大鼠心肌梗死后炎症反应的影响及机制[J]. 中华心血管病杂志, 2017, 45(6): 513-518. doi: 10.3760/cma.j.issn.0253-3758.2017.06.014
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: